Navigation Links
Cataract Surgery: A Bargain, Despite the Price
Date:9/23/2007

he said. "The costs are much lower, and the results are much better."

Patients can actually expect improved vision, rather than vision that simply won't get worse.

"When you're treating glaucoma or diabetic retinopathy, you're trying to prevent further visual impairment from occurring," Rein said. "With cataracts, you can restore their vision to what it was before."

Cataract surgery also helps keep older people entertained and more engaged, Zarbin said. "I think when you're older and have a less active lifestyle, things like reading and watching television gain a greater importance," he said.

"You also have to consider the cost of taking care of those patients if you didn't have the therapy to treat them. We are way ahead as a society by paying for those treatments, because they cost less than caring for all these debilitated and blind people," he added.

More information

To learn more about cataracts, visit the U.S. National Eye Institute.



SOURCES: Marco Zarbin, M.D., professor and chairman of the Institute of Ophthalmology and Visual Science, Newark, N.J.; David B. Rein, Ph.D., researcher with RTI International, Research Triangle Park, N.C.; U.S. National Eye Institute


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Advances in Treatment of Cataracts
2. Prevention of cataracts
3. Artificial lenses- Boon to cataract patients
4. Vitamin C to put off cataract
5. Eye colour is a component in cataract
6. PUFA reduces risk of cataract
7. Cooking with unflued stove can cause cataract
8. Airlines Pilot At Heightened Risk Of Having Cataracts
9. Understanding The Relationship With Diet And Cataract
10. Good News For Cataract Patients
11. Cataract incidence high among people on a high carbohydrate diet.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)... to have committed patent and ...2 /PRNewswire-FirstCall/ -- Mannatech,Incorporate...r of dietary,supplements and skin care solutions, ...orthern District of Texas found that Glycoproducts...Mannatech,s patent and,trademark relating to Ambro...
(Date:5/12/2008)...Assists Removal of 975 Cardiac ...12 /PRNewswire-FirstCall/ -- Spectranetics,Corpora...reviewed study,demonstrates Spectranetics, excimer...al of pacing and defibrillator leads. The study, "...e with Transvenous Lead,Extraction: Outcomes and C...
(Date:5/12/2008)...g been known that embryonic stem cells have the ab...cells, the exact mechanism as to how this occurs h...ers at the Hebrew University of Jerusalem and else... process, resolving a long-standing question as to...through selective activation or selective repressi...
(Date:5/12/2008)...tCall/ -- ULURU Inc. (Amex: ULU ),today reported ...h 31,2008., For the quarter ended March 31, 2008... was $1,815,000, or $0.03 per share, compared to a... corresponding period in 2007.,The first quarter 2...$497,000, which included stock option expense, amo...
Breaking Medicine News(10 mins):Health News:Jury Validates Key Mannatech Technology Patents Involving Its Ambrotose(R) Glyconutrient Products 2Health News:Jury Validates Key Mannatech Technology Patents Involving Its Ambrotose(R) Glyconutrient Products 3Health News:Safe Options for Cardiac Lead Removal: Study Published in Heart Rhythm Journal 2Health News:Safe Options for Cardiac Lead Removal: Study Published in Heart Rhythm Journal 3Health News:How embryonic stem cells develop into tissue-specific cells demonstrated 2Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 2Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 3Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 4Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 5Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 6
...ts and psychological treatments such as hypnothera... irritable bowel syndrome (IBS), say researchers ... but conventional physical treatments often do not...ients can feel that their symptoms are being ignor...
...ely consumed beverage and is regularly investigate...from breast cancer to heart disease. Among its com...s have been linked to lower insulin and uric acid .... These and other mechanisms suggest that coffee c...
... drinking culture at work curbs an individuals ove...ggests research published ahead of print in Occup...rs base their findings on a detailed analysis of w...and drinking behaviors in over 5,000 employees in ...
...seem to be linked to extremely low frequency elect...ad of print in Occupational and Environmental Med... Swiss railway workers, who were monitored for 30 ...s opted to study this group, because railway worke...
Other Medicine News:Health News:Hypnotherapy may Help Patients With Irritable Bowel Syndrome 2Health News:Four Cups of Coffee a Day may Cut Down the Risk of Gout 2Health News:Four Cups of Coffee a Day may Cut Down the Risk of Gout 3Health News:Workplace Drinking Culture Influences Alcohol Intake Elsewhere 2
(Date:5/8/2008)...irstCall/ -- AstraZeneca (NYSE:,AZN) today announc...cation,(sNDA) to the U.S. Food and Drug Administra...e) Extended-Release Tablets to seek approval for t..., including maintenance of,antianxiety effect. It ...atypical antipsychotic medicine in GAD. The submis...
(Date:5/8/2008)... -- Go Healthy (Pink Sheets: GOHE),announces the i...rade (R),in three medical settings with an expecte...ers around the country. Dr. William Bryan of the S... in the Texas Medical Center,will coordinate one c...sician for the Houston Astros and the former Medic...
(Date:5/7/2008)...nduction Dosing Regimen, SEATTLE, May 7 /PRNewswi...daq: TRBN ) today announced that its partner, Wye...E ), has commenced patient dosing in the next,Phas...eumatoid arthritis,(RA). In collaboration with Tru... SBI-087 and other CD20-directed products., The r...
(Date:5/7/2008)...ll/ -- Shire plc (LSE: SHP,Nasdaq: SHPGY), the gl...nounced findings from a new data analysis that was...AYTRANA(TM) (methylphenidate transdermal,system) b...ntion Deficit,Hyperactivity Disorder (ADHD). The f... has an established safety profile and effectively...
Breaking Medicine Technology:AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8Go Healthy Initiates Additional Clinical Tests on Cholesterade 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 3Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 4New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 2New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 3New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 4New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 5New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 6New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 7Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates 767 1Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates 767 2Hemoglobin uncovered 1126 1Hemoglobin uncovered 1126 2Ripe fruit preferred 1124 1Ripe fruit preferred 1124 2Virginia Commonwealth University to Study Genomics Based Diagnostic Test 3A 5625 1Virginia Commonwealth University to Study Genomics Based Diagnostic Test 3A 5625 2Virginia Commonwealth University to Study Genomics Based Diagnostic Test 3A 5625 3Virginia Commonwealth University to Study Genomics Based Diagnostic Test 3A 5625 4
...SIGA Technologies, Inc.,(NASDAQ: SIGA) announced t...guinea pig trial of its lead Lassa fever virus dru...ty Level 4 conditions at,the U.S. Army Medical Res...by Dr. Kathleen Cashman under the supervision of D...hemorrhagic fever,viruses at USAMRIID for over 12 ...
...drug withdrawal, CHICAGO, May 15, 2007 /PRNewswire... and physicians commissioned by the National,Heada... shows that,20 percent of migraine patients are cu...hat contain barbiturates or opioids and have,not b...ion for the,relief of migraines. , Migraines affec...
Other Medicine Technology:SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193 2SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193 3SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 2Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 3Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 5Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 6
... Stripe S600 ranks among Zebra's most popular prin...ount on consistent, reliable performance. The S600... real-time clock and Zebra Printer Management for ...an accommodate a full-sized roll of media within t...
...lt on the solid, tested XiIIIPlus platform, the R1...d level of on-demand printing flexibility in tag p...r seamless integration into enterprise systems, au...ultiple power levels, statistics tracking, easier ...
The industrys first 600 dpi printer the 96XiIII is unmatched for printing large amounts of bar code, text and graphics information in limited label space. This printer is ideal for applications that
The 105SL is the newest member of the Zebra S Series™, and its also the fastest, combining enhanced memory and processing capacity with rugged and reliable all-metal construction. Based on a pro
Medicine Products: